Rabusertib

Rabusertib (LY2603618) is a potent and selective inhibitor of Chk1 with an IC50 of 7 nM.

Product Specifications

CAS Number

911222-45-2

Product Name Alternative

LY2603618; IC-83

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Checkpoint Kinase (Chk)

Type

Reference compound

Related Pathways

Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/LY2603618.html

Concentration

10mM

Purity

99.98

Solubility

DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

BrC(C=C1NC(NC2=NC=C(N=C2)C)=O)=C(C=C1OC[C@H]3OCCNC3)C

Molecular Formula

C18H22BrN5O3

Molecular Weight

436.30

Precautions

H302, H315, H319, H335

References & Citations

[1]King C, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32 (2) :213-26.|[2]Wang G, et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One. 2013 Sep 30;8 (9) :e76662.